INSIGHT

MEDICA 2025 and the start of CleverSkin’s public journey

MEDICA 2025 mattered because it moved CleverSkin from internal development into external challenge. That is a different test. A team can become comfortable with its own assumptions; manufacturers, distributors, clinicians and strategic partners are less forgiving.

The useful outcome was not publicity. It was a better list of questions. Which product boundary is easiest to explain? What evidence would a serious partner need? Where does the manufacturing route create friction? Which conversations are commercial, and which are simply interest?

That is how we use events now. Not as proof that the market has accepted the product, but as a way to expose the programme to people who can find the weak points early.